Outcomes in COVID-19 alunacedase alfa studies

All studies   Mortality   Ventilation   Serious outcomes   RCTs   RCT mortality   All outcomes  
0 0.5 1 1.5+ All studies -31% 1 178 Improvement, Studies, Patients Relative Risk Mortality -31% 1 178 Ventilation 23% 1 178 RCTs -31% 1 178 Late -31% 1 178 Alunacedase alfa for COVID-19 c19early.org November 2025 Favorsalunacedase alfa Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ APN01-COVID-19 Bundgaard (DB RCT) -31% 1.31 [0.51-3.38] death 9/88 7/90 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Late treatment -31% 1.31 [0.51-3.38] 9/88 7/90 31% higher risk All studies -31% 1.31 [0.51-3.38] 9/88 7/90 31% higher risk 1 alunacedase alfa COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Effect extraction pre-specified(most serious outcome) Favors alunacedase alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ APN01-COVID-19 Bundgaard (DB RCT) -31% 1.31 [0.51-3.38] 9/88 7/90 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Late treatment -31% 1.31 [0.51-3.38] 9/88 7/90 31% higher risk All studies -31% 1.31 [0.51-3.38] 9/88 7/90 31% higher risk 1 alunacedase alfa COVID-19 mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Favors alunacedase alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ APN01-COVID-19 Bundgaard (DB RCT) 23% 0.77 [0.34-1.73] 9/88 12/90 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.53 Late treatment 23% 0.77 [0.34-1.73] 9/88 12/90 23% lower risk All studies 23% 0.77 [0.34-1.73] 9/88 12/90 23% lower risk 1 alunacedase alfa COVID-19 mechanical ventilation result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.53 Favors alunacedase alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ APN01-COVID-19 Bundgaard (DB RCT) -31% 1.31 [0.51-3.38] death 9/88 7/90 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Late treatment -31% 1.31 [0.51-3.38] 9/88 7/90 31% higher risk All studies -31% 1.31 [0.51-3.38] 9/88 7/90 31% higher risk 1 alunacedase alfa COVID-19 serious outcome c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Effect extraction pre-specified(most serious outcome) Favors alunacedase alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ APN01-COVID-19 Bundgaard (DB RCT) -31% 1.31 [0.51-3.38] death 9/88 7/90 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Late treatment -31% 1.31 [0.51-3.38] 9/88 7/90 31% higher risk All studies -31% 1.31 [0.51-3.38] 9/88 7/90 31% higher risk 1 alunacedase alfa COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Effect extraction pre-specified(most serious outcome) Favors alunacedase alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ APN01-COVID-19 Bundgaard (DB RCT) -31% 1.31 [0.51-3.38] 9/88 7/90 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Late treatment -31% 1.31 [0.51-3.38] 9/88 7/90 31% higher risk All studies -31% 1.31 [0.51-3.38] 9/88 7/90 31% higher risk 1 alunacedase alfa COVID-19 RCT mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.58 Favors alunacedase alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ APN01-COVID-19 Bundgaard (DB RCT) -31% 1.31 [0.51-3.38] death 9/88 7/90 Improvement, RR [CI] Treatment Control APN01-COVID-19 Bundgaard (DB RCT) 23% 0.77 [0.34-1.73] ventilation 9/88 12/90 Alunacedase alfa COVID-19 outcomes c19early.org November 2025 Favors alunacedase alfa Favors control